Tesamorelin is a lab-made copy of GHRH — growth-hormone-releasing hormone, the brain's natural "release growth hormone now" signal. In that sense it's a cousin of CJC-1295 and sermorelin. But it stands apart from them in one big way: tesamorelin is an FDA-approved medicine, sold as Egrifta, with a real human trial base behind it.
In plain terms: same basic mechanism as the research GHRH peptides — but this one actually cleared the regulatory bar for a specific condition.
What it is
Tesamorelin is a stabilised analog of GHRH(1-44) — the full-length growth-hormone-releasing hormone with a chemical modification (a hexenoyl group added to the front) that keeps the body from breaking it down as quickly1. Like every GHRH analog, it pulls the GHRH lever on the growth-hormone system: it tells the pituitary to release the body's own growth hormone, rather than adding growth hormone directly. The opposite lever — the ghrelin/GHS receptor — is the one ipamorelin uses.
What it's approved for
This is the key detail most summaries blur. Tesamorelin isn't approved as a general "growth-hormone booster." It's approved for one specific problem: reducing excess visceral fat (the deep abdominal fat around the organs) in adults with HIV-associated lipodystrophy — a fat-redistribution condition seen in some people on long-term HIV treatment2. The FDA approved it as Egrifta in 20102.
What the trials actually found
Tesamorelin's approval rests on genuine, placebo-controlled human trials — the kind most peptides in this family have never had:
| Study | Model | Key result | Year |
|---|---|---|---|
| Falutz et al. (NEJM)1 | Human RCT (n≈410, HIV lipodystrophy) | ~2 mg/day cut visceral fat sharply versus placebo over 26 weeks, and lowered triglycerides | 2007 |
| Pooled Phase 3 program2 | Human (~806 participants) | ~15% average reduction in visceral fat — the basis for FDA approval | 2010 |
| FDA approval (Egrifta)2 | US regulatory | First and still one of the few approved drugs targeting HIV-associated visceral fat | 2010 |
In plain terms: give it daily for about six months, and the deep belly fat measurably shrinks — a real, human, placebo-controlled result. That's a very different evidence footing from a research peptide known only from animal work.
How it compares within the class
Mechanistically, tesamorelin, CJC-1295, and sermorelin all do the same job — pull the GHRH lever3. The differences are about how each is stabilised and how long it lasts, and about regulatory status (tesamorelin vs CJC-1295). All three pull the same lever; they differ mainly in how long they pull it — and in whether they've been through the approval process.
Where to place it
Tesamorelin sits with CJC-1295 and sermorelin as GHRH analogs, opposite the GHS-agonist family (ipamorelin, GHRP-6/2). The full landscape is in growth-hormone secretagogues explained.
Latest research
- Tesamorelin's approved indication remains HIV-associated lipodystrophy, but it has since been studied in other settings where visceral fat matters — including trials examining liver fat (NAFLD/MASLD) in people with HIV — reflecting continued research interest in the GHRH mechanism.
- Reformulated versions of the drug have moved through the FDA in recent years, keeping tesamorelin a live, marketed medicine rather than a historical one2.
- We update this section as new results report.
The short version
Tesamorelin is a stabilised GHRH copy that prompts the body's own growth-hormone release — and, unusually for its family, it's an approved medicine (Egrifta, 2010) with real trials showing it reduces visceral fat in HIV-associated lipodystrophy. It shares a mechanism with the research peptides CJC-1295 and sermorelin; what sets it apart is the evidence and approval behind it. This is an educational overview, not medical advice.